Ключевые слова
депрессия
обзор литературы
Как цитировать
Аннотация
Среди всего многообразия клинических проявлений болезни Паркинсона особое место занимают нейропсихиатрические симптомы, среди которых депрессия выступает одним из наиболее часто встречающихся психических расстройств. Несмотря на накопленный значительный багаж знаний относительно этиологии, патогенеза, диагностики и терапии депрессивных расстройств, на сегодняшний день все еще остаются недостаточно проясненными некоторые важные аспекты взаимоотношений между депрессивными расстройствами и болезнью Паркинсона. Данный обзор посвящен анализу накопленных на сегодняшний день данных относительно особенностей клинической картины и терапии депрессий при болезни Паркинсона.Литература
1. Batzu L. et al. A general clinical overview of the nonmotor symptoms in Parkinson's disease: Neuropsychiatric symptoms // Int. Rev. Neurobiol. – 2024. – V. 174. – P. 59–97. DOI: 10.1016/bs.irn.2023.11.001.
2. Weintraub D. et al. The neuropsychiatry of Parkinson's disease: advances and challenges // Lancet Neurol. – 2022. – V. 21. – No 1. – P. 89–102. DOI: 10.1016/S1474-4422(21)00330-6.
3. Madabushi J.S. et al. Parkinson’s disease: diagnostic challenges amidst transdiagnostic and overlapping mental health symptoms // Cureus. – 2023. – V. 15. – No 3. – P. e36661. DOI: 10.7759/cureus.36661.
4. Cummings J.L. Depression and Parkinson's disease: a review // Am. J. Psychiatry. – 1992. – V. 149. – No 4. – P. 443–454. DOI: 10.1176/ajp.149.4.443.
5. Timmer M.H.M. et al. What a neurologist should know about depression in Parkinson's disease // Pract. Neurol. – 2017. – V. 17. – No 5. – P. 359–368. DOI: 10.1136/practneurol-2017-001650.
6. Рагимова А.А. и др. Нейропсихические симптомы болезни Паркинсона на немоторной стадии // Кремлевская медицина. Клинический вестник. – 2019. – V. 4. – P. 45–56. [Ragimova A.A. et al. Neuropsychiatric symptoms of Parkinson's disease at the non-motor stage // Kremlin Medicine. Clinical Bulletin. – 2019. – V. 4. – P. 45–56. In Russian]. DOI: 10.26269/qbn4-g055.
7. Bereau M. et al. Fatigue in de novo Parkinson's disease: expanding the neuropsychiatric triad? // J. Parkinsons Dis. – 2022. – V. 12. – No 4. – P. 1329–1337. DOI: 10.3233/JPD-213116.
8. Ehrt U. et al. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease // Int. J. Geriatr. Psychiatry. – 2006. – V. 21. – No 3. – P. 252–258. DOI: 10.1002/gps.1456.
9. Shepard M.D. et al. Suicide in Parkinson's disease // J. Neurol. Neurosurg. Psychiatry. – 2019. – V. 90. – No 7. – P. 822–829. DOI: 10.1136/jnnp-2018-319815.
10. Pontone G.M. et al. Optimal treatment of depression and anxiety in Parkinson's disease // Am. J. Geriatr. Psychiatry. – 2021. – V. 29. – No 6. – P. 530–540. DOI: 10.1016/j.jagp.2021.02.037.
11. Schrag A. et al. Depression rating scales in Parkinson’s Disease: critique and recommendations // Mov. Disord. – 2007. – V. 22 (8). – P. 1077–1092. DOI: 10.1002/mds.21333.
12. Assogna F. et al. Alexithymia in Parkinson’s disease: a systematic review of the literature // Parkinsonism Relat. Disord. – 2016. – V. 28. – P. 1–11. DOI: 10.1016/j.parkreldis.2016.03.021.
13. Costa A. et al. Alexithymia in Parkinson's disease: a point of view on current evidence // Neurodegener. Dis. Manag. – 2016. – V. 6. – No 3. – P. 215–222. DOI: 10.2217/nmt-2016-0001.
14. Sagar R. et al. Relationship between alexithymia and depression: a narrative review // Indian J. Psychiatry. – 2021. – V. 63. – No 2. – P. 127–133. DOI: 10.4103/psychiatry.IndianJPsychiatry_527_20.
15. Chendo I. et al. Frequency of depressive disorders in Parkinson's disease: a systematic review and meta-analysis // J. Parkinsons Dis. – 2022. – V. 12. – No 5. – P. 1409–1418. DOI: 10.3233/JPD-223207.
16. Slaughter J.R. et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease // J. Neuropsychiatry Clin. Neurosci. – 2001. – V. 13. – No 2. – P. 187–196. DOI: 10.1176/jnp.13.2.187.
17. Reijnders J.S.A.M. et al. A systematic review of prevalence studies of depression in Parkinson's disease // Mov. Disord. – 2008. – V. 23. – No 2. – P. 183–189. DOI: 10.1002/mds.21803.
18. Inoue T. et al. Depression and major depressive disorder in patients with Parkinson's disease // Mov. Disord. – 2010. – V. 25. – No 3. – P. 44–54. DOI: 10.1002/mds.22921.
19. Lee Y. et al. Morbidity and associated factors of depressive disorder in patients with Parkinson's disease // J. Nerv. Ment. Dis. – 2022. – V. 210. – No 10. – P. 777–783. DOI: 10.1097/NMD.0000000000001537.
20. Марута Н.А. и др. Депрессивные расстройства при болезни Паркинсона: клиника, диагностика, терапия // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2013. – Т. 113. – № 11 (2). – С. 42–47. [Maruta N.A. et al. Depressive disorders in Parkinson's disease: clinical features, diagnosis, therapy // S.S. Korsakov Journal of Neurology and Psychiatry. – 2013. – V. 113. – No 11 (2). – P. 42–47. In Russian].
21. Skorvanek M. et al. The associations between fatigue, apathy, and depression in Parkinson's disease // Acta Neurol. Scand. – 2015. – V. 131. – No 2. – P. 80–87. DOI: 10.1111/ane.12282.
22. Friedman J.H. et al. Fatigue in Parkinson's disease: a nine-year follow-up // Mov. Disord. – 2001. – V. 16. – No 6. – P. 1120–1122. DOI: 10.1002/mds.1201.
23. Harris E. et al. Apathy in patients with Parkinson disease as a function of side of onset // J. Geriatr. Psychiatry Neurol. – 2013. – V. 26. – No 2. – P. 95–104. DOI: 10.1177/0891988713481267.
24. Pagonabarraga J. et al. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment // Lancet Neurol. – 2015. – V. 14. – No 5. – P. 518–531. DOI: 10.1016/S1474-4422(15)00019-8.
25. Смулевич А.Б. Депрессии в клинической практике врачей общемедицинских специальностей // РМЖ. – 2011. – V. 19. – № 9. – С. 597–600. [Smulevich A.B. Depressions in the clinical practice of general practitioners // Russian Medical Journal. – 2011. – V. 19. – No 9. – P. 597–600. In Russian].
26. Martyna M.R. et al. Can (or Should) We Treat Depression and Anxiety in Parkinson's Disease Algorithmically? // Am. J. Geriatr. Psychiatry. – 2021. – V. 29. – No 6. – P. 541–543. DOI: 10.1016/j.jagp.2021.03.001.
27. Кичерова О.А. и др. Особенности депрессивных нарушений при болезни Паркинсона // Современные проблемы науки и образования. – 2024. – № 4. – С. 100. [Kicherova O.A. et al. Features of depressive disorders in Parkinson's disease // Modern Problems of Science and Education. – 2024. – No 4. – P. 100. In Russian]. DOI: 10.17513/spno.33623.
28. Angelopoulou E. et al. Pharmacological and non-pharmacological treatments for depression in Parkinson’s disease: an updated review // Medicina (Kaunas). – 2023. – V. 59. – No 8. – P. 1454. DOI: 10.3390/medicina59081454.
29. Choi C. et al. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease // J. Neurol. Sci. – 2000. – V. 172. – No 1. – P. 12–16. DOI: 10.1016/s0022-510x(99)00198-7.
30. Шиндряева Н.Н. и др. Применение прамипексола при болезни Паркинсона // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2015. – Т. 115. – № 6 (2). – С. 65–72. [Shindryaeva N.N. et al. Use of pramipexole in Parkinson's disease // S.S. Korsakov Journal of Neurology and Psychiatry. – 2015. – V. 115. – No 6 (2). – P. 65–72. In Russian]. DOI: 10.17116/jnevro20151156265-72.
31. Barone P. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial // Lancet Neurol. – 2010. – V. 9. – No 6. – P. 573–580. DOI: 10.1016/S1474-4422(10)70106-X.
32. Jiang D.-Q. et al. The role of pramipexole in the treatment of patients with depression and Parkinson's disease: a meta-analysis of randomized controlled trials // Asian J. Psychiatr. – 2021. – V. 61. – P. 102691. DOI: 10.1016/j.ajp.2021.102691.
33. Pahwa R. et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease // Neurology. – 2007. – V. 68. – No 14. – P. 1108–1115. DOI: 10.1212/01.wnl.0000258660.74391.c1.
34. Mueller C. et al. Assessment and management of neuropsychiatric symptoms in Parkinson's disease // CNS Drugs. – 2018. – V. 32. – No 7. – P. 621–635. DOI: 10.1007/s40263-018-0540-6.
35. Левин О.С. и др. Недвигательные флюктуации при болезни Паркинсона // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2010. – Т. 110. – № 3. – С. 90–96. [Levin O.S. et al. Non-motor fluctuations in Parkinson's disease // S.S. Korsakov Journal of Neurology and Psychiatry. – 2010. – V. 110. – No 3. – P. 90–96. In Russian].
36. Chikatimalla R., Dasaradhan T., Koneti J., Cherukuri S.P., Kalluru R., Gadde S. Depression in Parkinson's Disease: A Narrative Review // Cureus. – 2022. – V. 14. – No 8. – P. e27750. DOI: 10.7759/cureus.27750.
37. Chen J. et al. Comparative analysis of the effects of escitalopram, pramipexole, and transcranial magnetic stimulation on depression in patients with Parkinson disease: an open-label randomized controlled trial // Clin. Neuropharmacol. – 2022. – V. 45. – No 4. – P. 84–88. DOI: 10.1097/WNF.0000000000000507.
38. Xu F. et al. Efficacy and safety of newer-generation antidepressants medications in Parkinson's disease with depression – a meta-analysis of randomized controlled trials // J. Psychiatr. Res. – 2025. – V. 184. – P. 48–55. DOI: 10.1016/j.jpsychires.2025.02.044.
39. Aguera-Ortiz L. et al. Focus on depression in Parkinson's disease: a delphi consensus of experts in psychiatry, neurology, and geriatrics // Parkinsons Dis. – 2021. – Article ID 6621991. – P. 1–11. DOI: 10.1155/2021/6621991.
40. Richard I.H. et al. SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease // Neurology. – 2012. – V. 78. – No 16. – P. 1229–1236. DOI: 10.1212/WNL.0b013e3182516244.
41. Takahashi M. et al. Antidepressants for depression, apathy, and gait instability in Parkinson's disease: a multicenter randomized study // Internal Medicine. – 2018. – V. 58. – No 3. – P. 361–368. DOI: 10.2169/internalmedicine.1359-18.
42. Rukavina K. et al. Pain in Parkinson's disease: new concepts in pathogenesis and treatment // Current Opinion in Neurology. – 2019. – V. 32. – No 4. – P. 579–588. DOI: 10.1097/WCO.0000000000000711.
43. Iwaki H. et al. A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease // Journal of the Neurological Sciences. – 2020. – V. 414. – P. 116833. DOI: 10.1016/j.jns.2020.116833.
44. Matić T. et al. The effect of serotonin reuptake and serotonin-noradrenaline reuptake inhibitors on motor symptoms in Parkinson's disease: a PPMI-based matched-subject study // J. Parkinsons Dis. – 2024. – V. 14. – No 8. – P. 1642–1651. DOI: 10.1177/1877718X241296016.
45. Schade R.N. et al. Greater apathy associated with selective serotonin reuptake inhibitor use in Parkinson's disease // J. Geriatr. Psychiatry Neurol. – 2025. – V. 38. – No 1. – P. 13–22. DOI: 10.1177/08919887241254471.
46. McFarland D. et al. Selective serotonin reuptake inhibitor (SSRI) bleeding risk: considerations for the consult-liaison psychiatrist // Current Psychiatry Reports. – 2023. – V. 25. – No 3. – P. 113–124. DOI: 10.1007/s11920-023-01411-1.
47. Samushiya M.A. et al. The impact of mental illness on compliance with therapy in patients with Parkinson's disease // European Neuropsychopharmacology. – 2019. – V. 29. – No S6. – P. 519–520. DOI: 10.1016/j.euroneuro.2019.09.806.
48. Ivanov S.V. et al. Agomelatine in the treatment of depressive disorders in clinical practice: Multicenter observational CHRONOS study // Neuropsychiatric Disease and Treatment. – 2014. – V. 10. – P. 631–639. DOI: 10.2147/NDT.S58994.
49. Watanabe N. et al. Mirtazapine versus other antidepressive agents for depression // Cochrane Database of Systematic Reviews. – 2011. – V. 12. – P. CD006528. DOI: 10.1002/14651858.CD006528.pub2.
50. Costa F.H. et al. Depression in Parkinson’s disease: diagnosis and treatment // Arquivos de Neuro-Psiquiatria. – 2012. – V. 70. – No 8. – P. 617–620. DOI: 10.1590/s0004-282x2012000800011.
51. Dobkin R.D. et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial // Am. J. Psychiatry. – 2011. – V. 168. – No 10. – P. 1066–1074. DOI: 10.1176/appi.ajp.2011.10111669.
52. Seritan A. et al. Mindfulness-based cognitive therapy improves anxiety and depression in people with Parkinson's disease: evidence from two pilot clinical trials // The American Journal of Geriatric Psychiatry. – 2023. – V. 31. – No 10. – P. 11–12. DOI: 10.1016/j.jagp.2023.02.020.
53. Van Wegen E.E.H. et al. Non-pharmacological interventions for depression and anxiety in Parkinson’s disease // J. Parkinsons Dis. – 2024. – V. 14. – Suppl. 1. – P. S135–S146. DOI: 10.3233/JPD-230228.
54. Van der Heide A. et al. Stress and mindfulness in Parkinson's disease – a survey in 5000 patients // NPJ Parkinsons Dis. – 2021. – V. 7. – No 1. – P. 7. DOI: 10.1038/s41531-020-00152-9.
55. Dos Santos Duarte J. et al. Physical activity based on dance movements as complementary therapy for Parkinson's disease: effects on movement, executive functions, depressive symptoms, and quality of life // PLoS One. – 2023. – V. 18. – No 2. – P. e0281204. DOI: 10.1371/journal.pone.0281204.
56. Yang Y. et al. Efficacy and evaluation of therapeutic exercises on adults with Parkinson's disease: a systematic review and network meta-analysis // BMC Geriatr. – 2022. – V. 22. – No 1. – P. 813. DOI: 10.1186/s12877-022-03510-9.
57. Makkos A. et al. High-frequency repetitive transcranial magnetic stimulation can improve depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study // Neuropsychobiology. – 2016. – V. 73. – No 3. – P. 169–177. DOI: 10.1159/000445296.
58. Wang M. et al. Repetitive transcranial magnetic stimulation improves cognition, depression, and walking ability in patients with Parkinson's disease: a meta-analysis // BMC Neurol. – 2024. – V. 24. – No 1. – P. 490. DOI: 10.1186/s12883-024-03990-9.